Archives
-
CHI3L1-IN-5: Astrocyte Assay Workflows
2026-09-12
CHI3L1-IN-5, also called Compound Z17, supports a paired workflow that connects CHI3L1-mediated NF-κB signaling with astrocyte Aβ handling and lysosomal recovery. This guide separates target-pathway evidence from functional rescue, helping researchers optimize exposure, controls, and interpretation without confusing this neuroinflammation tool with an unrelated ALDH2 compound that shares the Z17 label.
-
Cy7 NHS Ester: Practical Labeling and QC Guide
2026-09-11
Cy7 NHS ester (SKU A8109) is a water-soluble, sulfonated near-infrared reagent for labeling accessible amino groups on proteins, peptides, and related biomolecules. It is useful for aqueous conjugation and near-infrared imaging workflows, but it is not appropriate for targets without accessible amines or for long-term storage of prepared dye solutions.
-
Bone Transport and TGF-β1 in Diabetic Foot Ulcers
2026-09-11
A 2026 rat study identifies TGF-β1/TGFBR1 signaling as a mechanistic link between bone transport, angiogenesis, immune regulation, and diabetic foot ulcer repair. Its combination of proteomics, molecular assays, and pathway inhibition supports a model in which osteogenic injury generates signals that coordinate vascular and immune responses, while also highlighting important limits for translation.
-
HABA Workflows for PLGA Particle Research
2026-09-10
HABA converts avidin–biotin recognition into a practical absorbance assay for measuring biotin accessibility on engineered PLGA microspheres. Used alongside particle sizing and HPLC, it helps distinguish surface chemistry performance from drug loading and release behavior.
-
(5Z)-7-Oxozeaenol: Selective TAK1 Inhibitor
2026-09-10
(5Z)-7-Oxozeaenol is a potent, selective TAK1 inhibitor for dissecting IL-1-driven NF-κB and JNK/p38 MAPK signaling. Product information reports an approximately 8.1 nM purified-TAK1 IC50, cellular activity at 500 nM, and reduced ear swelling in a topical picryl chloride inflammation model.
-
Guanabenz Acetate in Stress-Response Assays
2026-09-09
Guanabenz Acetate enables controlled interrogation of α2-adrenergic receptor signaling alongside stress-granule and innate-immune readouts. This workflow translates findings from SARS-CoV-2 GADD34 research into testable, non-viral assay designs without overstating an unproven antiviral effect.
-
Diuron Research Workflows for Toxicology
2026-09-09
Diuron supports controlled studies spanning photosynthesis inhibition, plant biology research, and environmental toxicology. This workflow-focused guide shows how to prepare the compound, model renal injury in HK-2 cells, connect molecular readouts to pathway evidence, and troubleshoot common assay failures.
-
Calpain Inhibitor I, ALLN: Practical Lab Guide
2026-09-08
Calpain Inhibitor I, ALLN (SKU A2602) is a research reagent for probing calpain- and cathepsin-associated proteolysis in apoptosis assays, inflammation research, and ischemia-reperfusion injury models. It is water-insoluble and should be prepared in DMSO with matched vehicle controls; it is not a diagnostic, therapeutic, or exclusively calpain-specific reagent.
-
Separating Growth Inhibition from Cancer Cell Death
2026-09-08
Schwartz’s dissertation shows why relative viability and fractional viability should not be treated as interchangeable measures of anticancer activity. Its central contribution is a framework for distinguishing proliferative arrest from cell killing and for interpreting their different magnitudes and timing in vitro.
-
Tyrothricin Workflows for Antimicrobial Research
2026-09-07
Tyrothricin is a membrane-active peptide antibiotic mixture suited to dose-response, time-kill, bacterial, and fungal assay development. This guide connects practical antimicrobial workflows with the reference study’s glia-to-neuron mitochondrial-transfer model, while clearly separating validated observations from exploratory assay recommendations.
-
Puromycin dihydrochloride: Protocol and QC Guide
2026-09-07
Puromycin dihydrochloride provides a practical way to select and maintain cells expressing the pac resistance gene while supporting controlled studies of translation and ribosome activity. It should be optimized for each cell type and assay rather than applied as a universal concentration, and its use as an autophagy stimulus requires separate validation.
-
L-Ornithine and the Liver–Brain Metabolic Axis
2026-09-05
L-Ornithine is more than a urea cycle intermediate: emerging evidence positions hepatic OTC activity and ornithine accumulation within a liver–brain mechanism of astrocyte dysfunction. This article outlines how translational researchers can use L-Ornithine to connect metabolic enzyme assays, amino acid metabolism research, and mechanistic neurotoxicity studies.
-
m-PBA-Modified PAD4 Inhibitors Block Tumor NETs
2026-09-04
The 2023 European Journal of Medicinal Chemistry study developed phenylboronic acid-modified PAD4 inhibitors to improve tumor targeting through recognition of sialic acid residues. Its lead compound, 5i, inhibited the PAD4–H3cit–NET pathway, reduced primary tumor growth and metastasis in mouse models, and altered the tumor immune microenvironment without the direct tumor-cell cytotoxicity associated with conventional chemotherapy.
-
CFDA SE Cell Tracer Kit: Practical Workflow
2026-09-04
The CFDA SE Cell Tracer Kit provides persistent fluorescent labeling for cell proliferation studies, cell lineage tracing, and live-cell tracking workflows. It is appropriate for covalent, multi-day labeling but should not be treated as a reversible stain or used without optimization when exact labeling concentration, incubation time, or real-time physiological readouts are required.
-
RNA Pol II Loss Activates Apoptotic Signaling
2026-09-03
Harper et al. show that RNA Pol II inhibition kills cells through an active apoptotic program triggered by loss of hypophosphorylated RNA Pol IIA, rather than through transcriptional collapse alone. Their functional-genomics and drug-profiling strategy defines the Pol II degradation-dependent apoptotic response, or PDAR, and provides a framework for interpreting anticancer drug lethality.